Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Atom Therapeutics / Equity Capital Markets

<ul>
<li>Atom Therapeutics, a China-based clinical-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC is the sole sponsor.</li>
<li>In this note, we look at the company’s core product, ABP-671.</li>
<li>We also look at the company’s pre-IPO investors and management team.</li>
</ul>


Atom Therapeutics, a China-based clinical-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC is the sole sponsor.
In this note, we look at the company’s core product, ABP-671.
We also look at the company’s pre-IPO investors and management team.


Atom Therapeutics (新元素) Pre-IPO Quick Take: Moderate Innovation and Intense Competition

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Atom Therapeutics (ATOM HK)

Atom Therapeutics (新元素) Pre-IPO Quick Take: Moderate Innovation and Intense Competition

China's Atom Therapeutics aims to raise $100 million through a Hong Kong listing with CITIC as the sponsor. We look at their core product ABP-671,...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Atom Therapeutics (新元素) Pre-IPO Quick Take: Moderate Innovation and Intense Competition

​China's Atom Therapeutics aims to raise $100 million through a Hong Kong listing with CITIC as the sponsor. We look at their core product ABP-671,...

Ke Yan, CFA, FRM

China's Atom Therapeutics aims to raise $100 million through a Hong Kong listing with CITIC as the sponsor. We look at their core product ABP-671,...